Skip to content
Menu

BTIG Maintains Buy on Zevra Therapeutics, Lowers Price Target to $21

Benzinga Newsdesk 6 days ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

BTIG analyst Kambiz Yazdi maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $24 to $21.

BTIG analyst Kambiz Yazdi maintains Zevra Therapeutics (NASDAQ:ZVRA) with a Buy and lowers the price target from $24 to $21.

Read at benzinga.com